LIGANDAL
Ligandal is solving the delivery problem and enabling precision genetic medicine. By enabling cell- and tissue-specific delivery of gene therapies and editors such as CRISPR and mRNA, using synthetic peptides as targeting modalities, we develop and deliver therapeutic solutions for creating the next generation of medicine.
A combination of machine learning, chemistry, nanotechnology and biological studies intertwines our approach for rapid discovery, design and development of novel peptide therapeutics and delivery systems geared for the 21st century of medicine, backed by ten years of foundational R&D and 57 pending global patents.
li·gand
noun
BIOCHEMISTRY
a molecule that binds to another (usually larger) molecule.
Imagine a world where we can reprogram biology precisely and predictively for the betterment of humankind and the planet. We believe in that world and want to see the ultimate good for global health and longevity arise from these capabilities and technologies, their implementation, and their distribution.
Ligandal is a leader in the interface of computational biology, machine learning, and AI with nanomaterials and delivery technologies for developing the next generation of precision medicine. Our platform of peptide-based nanomaterials enables applications for gene therapy, gene editing, regenerative medicine, immunotherapy, and next-generation antidote-vaccine technologies to benefit our civilization.
Ligandal is akin to the invention of GPS and shipping routes for molecular delivery technologies. We make technologies such as mRNA and CRISPR, which are foundational to gene therapy and editing, able to reach their targets. Effectively, this expands the addressable "zip codes" of biology and therapeutics.
A combination of machine learning, chemistry, nanotechnology and biological studies intertwines our approach for rapid discovery, design and development of novel peptide therapeutics and delivery systems geared for the 21st century of medicine, backed by ten years of foundational R&D and 57 pending global patents.
li·gand
noun
BIOCHEMISTRY
a molecule that binds to another (usually larger) molecule.
Imagine a world where we can reprogram biology precisely and predictively for the betterment of humankind and the planet. We believe in that world and want to see the ultimate good for global health and longevity arise from these capabilities and technologies, their implementation, and their distribution.
Ligandal is a leader in the interface of computational biology, machine learning, and AI with nanomaterials and delivery technologies for developing the next generation of precision medicine. Our platform of peptide-based nanomaterials enables applications for gene therapy, gene editing, regenerative medicine, immunotherapy, and next-generation antidote-vaccine technologies to benefit our civilization.
Ligandal is akin to the invention of GPS and shipping routes for molecular delivery technologies. We make technologies such as mRNA and CRISPR, which are foundational to gene therapy and editing, able to reach their targets. Effectively, this expands the addressable "zip codes" of biology and therapeutics.
SEE OUR PUBLICATION: PEPTIDE ANTIDOTES TO SARS-COV-2 (COVID-19)
